By Dr. Bruce Ramshaw, Chief Medical Informatics Officer, Caresyntax
As the robotics community gathers for the 2025 Society of Robotic Surgery (SRS) annual meeting, the conversation is maturing. We’ve moved from asking “what’s possible?” to “where’s the value?”
This two-part series explores that question—starting with today’s reality: despite rapid innovation, the robotic surgery space faces a critical evidence gap. Clinical and financial returns remain unclear for many systems. In part one, I’ll outline why data is essential to assess and improve value. In part two, we’ll examine how leading robotic platforms are using real-world data to earn trust, drive adoption, and justify investment from hospitals and health systems.
Robotic Surgery: Evidence Over Hype
The robotic surgery market is booming, projected to grow from $11.8 billion in 2024 to $30–50 billion by 2030. U.S. hospitals alone will spend nearly $19 billion annually by the end of the decade. Yet this impressive growth doesn’t guarantee better outcomes—or better value.
More than 15 surgical robotic platforms have been FDA-cleared in recent years, ranging from compact, single-port systems to advanced platforms with any number of arms integrating AI and computer vision. This surge in innovation highlights both the growing complexity and fragmentation of the field. Yet performance still varies widely—driven not only by device design, but also by surgeon experience, procedure type, and how well the system integrates into the broader OR environment.
The only way to meaningfully compare new FDA approved devices – and drive improvement – is through robust, real-world data.
The Reality Check
Regulatory approval doesn’t equal proven value. Even dominant players like Intuitive, with over 9,900 systems and 2.7 million procedures annually, haven’t consistently demonstrated superior outcomes across all surgical types.
At Caresyntax, our Clinical Data as a Service (CDaaS) framework gives hospitals and industry partners the tools to measure what matters: patient outcomes, cost of care, and operational impact. Here are a few examples of what we’ve uncovered:
- University of Iowa: Our 2024 study revealed robotic small hernia repairs generated a loss of $881 per patient. In contrast, traditional repairs yielded over $3,200 in profit. Only large hernia repairs (10cm+) showed net positive returns with robotics.
- Atrium Health®: Partnering on a clinical quality improvement initiative (CQI), we found that using AirSeal® reduced average hospital stay from 3.0 to 1.8 days (p = 0.010) without increasing costs.
- Indiana Hernia Center: Evaluating over 300 OviTex® mesh cases, we saw 1.3% recurrence and 1% chronic pain—evidence of exceptional patient outcomes and experience.
These aren’t abstract numbers – they reflect real lives improved through precise, data-driven decisions.
The Path Forward
Hospitals face high-stakes investment decisions amid a flood of marketing claims. Unfortunately, the current regulatory framework doesn’t require rigorous post-market outcome validation. That’s where real-world data steps in.
To evaluate surgical robotics meaningfully, we need to move beyond anecdotes and siloed metrics. We must integrate financial, clinical, and operational insights—spanning the entire episode of care. It’s the only path to sustainable adoption and trust.
The next wave of robotics success won’t be won with flashy features – it will be built on evidence.
Coming Next: Robotic Vendors Who Are Doing It Right
In part two of this series, we’ll highlight forward-thinking companies that are setting new standards – using real-world data to validate performance, differentiate their platforms, and forge meaningful partnerships with health systems.
